Skip to main content

Eli Lilly — Portfolio, Page 6

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

158
Companies
$7.3B
Total invested
$55.2M
Avg. check
21
Industries
Biotechnology 20Health Care 11Medical 8Life Science 5Therapeutics 5Pharmaceutical 3+15 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 121144 of 158
Revisto
November 2024

Revisto is a pioneer AI-powered technology that simplifies the medical, legal, and regulatory review process for life sciences marketing.

Artificial Intelligence (AI) · Austin$4.0M Seed
Beta Bionics
November 2024

Beta Bionics is a biotechnology company that provides software to reduce the burden of diabetes care.

Biotechnology · Irvine$60.0M Series E
Sunbird Bio
October 2024

Sunbird Bio is a diagnostics platform developer that aims to give molecular diagnostics with faster outcomes.

Biotechnology · Singapore$14.0M Series Unknown
Aktis Oncology
September 2024

Aktis Oncology is a biotechnology company that designs and develops novel class radiopharmaceuticals.

Biotechnology · Boston$175.0M Series B
basys.ai
September 2024

Basys.ai automates the process of prior authorization and utilization management for health plans/payers using an AI-based platform.

Artificial Intelligence (AI) · Cambridge$25K Seed
NanoSyrinx
September 2024

NanoSyrinx is a discovery stage biotechnology company based at the University of Warwick’s Medical School.

Biotechnology · Coventry$13.1M Series A
OrsoBio
September 2024

OrsoBio is a clinical-stage biopharmaceutical company that develops therapies to treat severe metabolic disorders.

Biopharma · Palo Alto$67.0M Series B
Circle Pharma
September 2024

Circle Pharma is a biotechnology company creating bioavailable macrocyclic peptide therapeutics that target protein-protein interactions.

Biotechnology · San Francisco$90.0M Series D
RetiSpec
July 2024

RetiSpec is a medical imaging startup developing an eye scanner for early detection of Alzheimer’s Disease pathology.

Health Care · Toronto$10.0M Series A
Myricx Bio
July 2024

Myricx Bio is a biotechnology company that develops novel NMT inhibitor payloads for ADCs to treat cancer.

Biotechnology · London$115.3M Series A
Vanqua Bio
July 2024

Vanqua Bio is a biotechnology company that discovers and develops next-generation medicines for patients with neurodegenerative diseases.

Biotechnology · Chicago$45.0M Series Unknown
Radar Therapeutics
May 2024

Radar Therapeutics pioneer in treatment modality, precision-expressed mRNA-based therapeutics.

Medical · Berkeley$13.4M Seed
Lycia Therapeutics
May 2024

Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras.

Biotechnology · South San Francisco$106.6M Series C
Blacksmith Medicines
February 2024

Blacksmith Medicines developing medicines targeting metal-dependent enzymes found in human physiology.

Biotechnology · San Diego$3.3M Grant
Firefly Bio
February 2024

Firefly Bio specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.

Biotechnology · San Francisco$94.0M Series A
ViaNautis
November 2023

ViaNautis is at the forefront of developing novel medications capable of crossing biological barriers.

Biopharma · Cambridge$24.6M Series A
Sitryx Therapeutics
September 2023

Sitryx is a biopharmaceutical company develops disease modifying therapeutics in immuno-oncology and immuno-inflammation.

Biotechnology · Oxford$39.0M Series A
Mariana Oncology
September 2023

Mariana Oncology is a biotechnology research industry.

Bioinformatics · Watertown$175.0M Series B
Amber Bio
August 2023

Amber Bio is a biotechnology company pioneering new gene editing modalities using multi-kilobase edits.

Biotechnology · San Francisco$26.0M Seed
AltPep
June 2023

AltPep provides a novel approach for tackling amyloid diseases, with diagnostic, therapeutic and anti-biofilm applications.

Biotechnology · Seattle$52.9M Series B
Mozart Therapeutics
June 2023

Mozart is a biotech startup focusing on the development of disease-modifying therapies for autoimmune and inflammatory diseases.

Biotechnology · Seattle$25.0M Series A
Nido Biosciences
May 2023

Nido Biosciences is a clinical-stage company that develops precision medicines for severe neurological diseases.

Biotechnology · Watertown$86.6M Series B
DiogenX
May 2023

DiogenX is a preclinical stage biotech company specializing in the development of pancreatic beta-cell modulators.

Biotechnology · Marseille$36.8M Series A
IgGenix
February 2023

IgGenix is a biotechnology company.

Biotechnology · San Francisco$40.0M Series B

Where Eli Lilly invests

Biotechnology20
Health Care11
Medical8
Life Science5
Therapeutics5
Pharmaceutical3

About Eli Lilly's portfolio

How many companies has Eli Lilly invested in?

Eli Lilly has invested in 158 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Eli Lilly invest in?

Eli Lilly's top investment sectors include Biotechnology, Health Care, Medical, Life Science, Therapeutics. The firm invests across 21 different industry categories.

What is Eli Lilly's largest investment?

Among tracked funding rounds, Aktis Oncology received $175.0M in a Series B round. Eli Lilly's total known invested capital is $7.3B.

What is the average investment size for Eli Lilly?

Eli Lilly's average investment size is $55.2M across its portfolio of 158 companies.

What are Eli Lilly's most recent investments?

Recent Eli Lilly portfolio additions include Revisto, Beta Bionics, Sunbird Bio, Aktis Oncology, basys.ai. These companies were founded in 2020 or later.

Reach the founders behind these 158 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →